Enhanced Antitumor Efficacy of Combined PTC596 and PD1 Blockade in Hepatocellular Carcinoma [0.03%]
PTC596联合PD1阻断在肝细胞癌中的协同抗肿瘤作用增强效应
Tingting Qiao,Shaoping Wang,ChenXing Wang et al.
Tingting Qiao et al.
PTC596 has been studied in advanced solid tumors in clinical trials. However, the effects of PTC596 alone or in combination with programmed cell death protein-1 (PD1) blockade in hepatocellular carcinoma (HCC) remain unclear. Subcutaneous t...
Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses [0.03%]
合成感应型细菌可调节难治性肿瘤微环境，增强免疫检查点抑制剂的治疗效应
Myrofora Panagi,Fotios Mpekris,Marcos Burger Ramos et al.
Myrofora Panagi et al.
Immunotherapy has transformed cancer treatment but remains ineffective in many solid tumors, largely due to the immunosuppressive tumor microenvironment (TME). A dense/stiff extracellular matrix (ECM) can hinder immune cell infiltration, li...
Dual inhibition of PARP and ATR induces synthetic lethal vulnerability in prostate cancer with CDK12 deficiency [0.03%]
PARP和ATR的双重抑制诱导前列腺癌中CDK12缺陷合成致死性缺陷中的脆弱性
Yuki Kamiyama,Takuro Sunada,Yutaka Kanoh et al.
Yuki Kamiyama et al.
Prostate cancers (PCa) harboring CDK12 alterations exhibit aggressive clinical behavior and poor responses to current therapeutic strategies. Although CDK12 is categorized as a homologous recombination repair (HRR)-related gene, clinical ev...
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations [0.03%]
BLU-451：一种针对罕见EGFR突变的强效且选择性的具有中枢神经系统活性的小分子抑制剂
Yves A Millet,Alexander I Spira,Christina S Baik et al.
Yves A Millet et al.
BLU-451 is a potent and selective tyrosine kinase inhibitor designed to target uncommon epidermal growth factor receptor (EGFR) mutations, spare wild-type EGFR, and be active in the central nervous system (CNS). In vitro EGFR enzyme assays ...
A Bispecific Anti-Fluorescein × Anti-CD3 T-cell Engager in Combination with Fluoresceinated Adaptors Enables Lysis of AML Cells [0.03%]
双特异性的抗荧光素×抗CD3 T细胞衔接器与荧光素衍生物配合使用可裂解AML细胞
Laura G Volta,Celeste Gobbi,Christian Koch et al.
Laura G Volta et al.
Tumor-targeting antibodies, antibody-drug conjugates, and radionuclide antibody conjugates are established therapeutic tools in clinical use. Furthermore, bispecific T cell-engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T ce...
Samuel Parry,Charley Q Jang,Alessandro Leal et al.
Samuel Parry et al.
Advanced solid tumors remain largely incurable, with most patients ultimately progressing despite modern therapies, including immune checkpoint blockade. The limited impact of these approaches reflects the biological complexity of solid tum...
Tri-specific Humabody CB307 Targeting CD137, Prostate-specific Membrane Antigen, and Human Serum Albumin Whole-body Biodistribution Measured with 89Zr-CB307 PET [0.03%]
三特异性Humabody CB307靶向CD137、前列腺膜抗原和人血清白蛋白以及使用89Zr标记CB307进行全身PET成像研究
Daan G Knapen,Claudia Aj van Winkel,Tom Grevelink et al.
Daan G Knapen et al.
This study investigated (pre)clinically the biodistribution of the tri-specific Humabody® CB307, composed of three heavy variable domains (VHs) targeting prostate-specific membrane antigen (PSMA), CD137, and human serum albumin (HSA). CB30...
CDK2 Inhibition and Eradication of Aneuploid Cancers: Promise Meets Resistance [0.03%]
CDK2抑制与非整倍体癌的根除：前景与抗性并存
Samuel C Okpechi,Zibo Chen,Liliya Tyutyunyk-Massey et al.
Samuel C Okpechi et al.
Aneuploidy is a cancer hallmark that causes resistance to anticancer drugs and promotes aggressive tumors. Thus, aneuploidy is a consequential feature of human malignancy. This review addresses how cyclin dependent kinase 2 (CDK2) inhibitio...
Oncolytic Herpes Virus G47∆ Potentiates ADCC-Inducing Molecular Targeted Therapy via Coordinated Activation of Innate and Adaptive Immune Responses [0.03%]
溶瘤 herpes病毒G47∆通过协调激活先天性和适应性免疫反应增强抗体依赖的细胞介导的细胞毒作用诱导分子靶向治疗
Takafumi Nagatomo,Miwako Iwai,Minoru Tanaka et al.
Takafumi Nagatomo et al.
Antibody-dependent cellular cytotoxicity (ADCC) is a key player in the antitumor immunity elicited through molecular targeted therapy of oncogenic receptors using monoclonal antibodies (mAbs). Oncolytic viruses represent an alternative ther...
Potent anti-tumor activity of the AXL-targeted antibody-drug conjugate, mipasetamab uzoptirine (ADCT-601), in preclinical models of adenoid cystic carcinoma [0.03%]
针对AXL的抗体药物偶联物mipasetamab uzoptirine（ADCT-601）在腺样囊性癌的临床前模型中显示出强大的抗肿瘤活性
Joseph O Humtsoe,Leilani Jones,Anita Pothukuchi et al.
Joseph O Humtsoe et al.
Adenoid cystic carcinoma (ACC) is a rare salivary gland malignancy with no FDA-approved systemic therapies and limited benefit from conventional treatments. Proteogenomic profiling has revealed consistent overexpression of AXL, providing a ...